Provided by Tiger Trade Technology Pte. Ltd.

Pieris Pharmaceuticals

13.60
0.0000
Volume:- -
Turnover:743.03K
Market Cap:17.96M
PE:-1.09
High:13.60
Open:13.60
Low:13.60
Close:13.60
52wk High:22.32
52wk Low:6.20
Shares:1.32M
Float Shares:776.02K
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.5338
EPS(LYR):-21.8005
ROE:-68.21%
ROA:-28.31%
PB:1.10
PE(LYR):-0.62

Loading ...

Company Profile

Company Name:
Pieris Pharmaceuticals
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.